ライフサイエンスコーパス: polymorphic ventricular tachycardia

1 romes (e.g., flecainide in catecholaminergic polymorphic ventricular tachycardia).

2 rhythmia and sudden death (catecholaminergic polymorphic ventricular tachycardia).

3 mphetamine, marijuana, and catecholaminergic polymorphic ventricular tachycardia.

4 in an established model of catecholaminergic polymorphic ventricular tachycardia.

5 tically modified mice with catecholaminergic polymorphic ventricular tachycardia.

6 ome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia.

7 n CASQ2 has been linked to catecholaminergic polymorphic ventricular tachycardia.

8 te as [corrected] "shifting" foci resembling polymorphic ventricular tachycardia.

9 ons and extrasystolic Ca2+ waves, leading to polymorphic ventricular tachycardia.

10 dentified in patients with catecholaminergic polymorphic ventricular tachycardia.

11 nged QT intervals, QT interval lability, and polymorphic ventricular tachycardia.

12 variant classification in catecholaminergic polymorphic ventricular tachycardia.

13 ression represent a novel inherited cause of polymorphic ventricular tachycardia.

14 ifth) paper will deal with catecholaminergic polymorphic ventricular tachycardia.

15 nherited disorders such as catecholaminergic polymorphic ventricular tachycardia.

16 und to underlie the mechanism of spontaneous polymorphic ventricular tachycardia.

17 gthy delay to diagnosis in catecholaminergic polymorphic ventricular tachycardia.

18 outcomes in children with catecholaminergic polymorphic ventricular tachycardia.

19 ong-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia.

20 tic denervation in LQTS or catecholaminergic polymorphic ventricular tachycardia.

21 , cardiac hypertrophy, and catecholaminergic polymorphic ventricular tachycardia.

22 as the long-QT syndrome or catecholaminergic polymorphic ventricular tachycardia.

23 lve RyRs, such as malignant hyperthermia and polymorphic ventricular tachycardia.

24 iac arrhythmias, including catecholaminergic polymorphic ventricular tachycardia.

25 tricular noncompaction and catecholaminergic polymorphic ventricular tachycardia.

26 rome, Brugada Syndrome, or Catecholaminergic Polymorphic Ventricular Tachycardia.

27 rhythmogenic mechanism for catecholaminergic polymorphic ventricular tachycardia.

28 other raised suspicion for catecholaminergic polymorphic ventricular tachycardia.

29 n that was consistent with catecholaminergic polymorphic ventricular tachycardia.

30 cytes, and correlated with catecholaminergic polymorphic ventricular tachycardia.

31 gaming-associated event (3 catecholaminergic polymorphic ventricular tachycardia, 1 long QT syndrome,

32 Complications other than AV block included polymorphic ventricular tachycardia 10 to 24 h after the

33 syndrome, 3/18 (17%); and catecholaminergic polymorphic ventricular tachycardia, 2/18 (11%).

34 ted patients were sustained and nonsustained polymorphic ventricular tachycardia (3.6%).

35 e, 9; Brugada syndrome, 8; catecholaminergic polymorphic ventricular tachycardia, 3; short QT syndrom

36 ng Long-QT syndrome (13%), catecholaminergic polymorphic ventricular tachycardia (4%), arrhythmogenic

37 disease factors (18; 38%; catecholaminergic polymorphic ventricular tachycardia [6], near-drowning [

38 ts, increased susceptibility to induction of polymorphic ventricular tachycardia (60 vs. 24% in Kcne5

39 noncompaction (7%), and 1 catecholaminergic polymorphic ventricular tachycardia (7%).

40 f-function mutations cause catecholaminergic polymorphic ventricular tachycardia, a condition charact

41 was sufficient to prevent catecholaminergic polymorphic ventricular tachycardia, a congenital source

42 CASQ2) genes are linked to catecholaminergic polymorphic ventricular tachycardia, a life-threatening

43 have been associated with catecholaminergic polymorphic ventricular tachycardia and a form of arrhyt

44 ndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia and Brugada syndrome

45 mural reentry over transmural reentry during polymorphic ventricular tachycardia and fibrillation.

46 cardiac diseases, such as catecholaminergic polymorphic ventricular tachycardia and heart failure (H

47 ird proband diagnosed with catecholaminergic polymorphic ventricular tachycardia and his father with

48 ) in genes associated with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome

49 ed the predominant role of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome

50 tiologies established were catecholaminergic polymorphic ventricular tachycardia and long QT syndrome

51 an in-depth review of the different forms of polymorphic ventricular tachycardia and propose a practi

52 d premature ventricular beats with bursts of polymorphic ventricular tachycardia and then died sudden

53 ontaneous ventricular arrhythmias, including polymorphic ventricular tachycardia and ventricular fibr

54 iac arrest secondary to multiple episodes of polymorphic ventricular tachycardia and ventricular fibr

55 r in which mutation carriers are at risk for polymorphic ventricular tachycardia and/or sudden cardia

56 logists: long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrom

57 ventricular fibrillation, catecholaminergic polymorphic ventricular tachycardia, and risk of sudden

58 ome; 4 long-QT syndrome; 1 catecholaminergic polymorphic ventricular tachycardia; and 2 cardiomyopath

59 s with clinically definite catecholaminergic polymorphic ventricular tachycardia are classified ambig

60 ered the treatment of choice for one form of polymorphic ventricular tachycardia, are contraindicated

61 ns in long QT syndrome and catecholaminergic polymorphic ventricular tachycardia-associated genes in

62 o predict pathogenicity of catecholaminergic polymorphic ventricular tachycardia-associated RYR2 VUS

63 roperties of wild-type and catecholaminergic polymorphic ventricular tachycardia-associated RyR2(R449

64 One exception is the catecholaminergic polymorphic ventricular tachycardia-causing N53I substit

65 A polymorphic ventricular tachycardia closely resembling T

66 thmia syndromes, including catecholaminergic polymorphic ventricular tachycardia, congenital long QT

67 rome (BrS) (n = 16 [14%]), catecholaminergic polymorphic ventricular tachycardia (CPVT) (n = 9 [8%]),

68 ecently been identified in catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmo

69 mutations associated with catecholaminergic polymorphic ventricular tachycardia (CPVT) and atrial fi

70 ong QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) and deal spec

71 cause arrhythmias such as catecholaminergic polymorphic ventricular tachycardia (CPVT) and long QT s

72 Catecholaminergic polymorphic ventricular tachycardia (CPVT) and short QT

73 Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk f

74 ong QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) are electric

75 mutations associated with catecholaminergic polymorphic ventricular tachycardia (CPVT) are postulate

76 Catecholaminergic polymorphic ventricular tachycardia (CPVT) causes sudden

77 ation R33Q leads to lethal catecholaminergic polymorphic ventricular tachycardia (CPVT) implies a cru

78 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a conditio

79 Catecholamine-induced polymorphic ventricular tachycardia (CPVT) is a familial

80 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial

81 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic

82 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a lethal,

83 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentia

84 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentia

85 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentia

86 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inh

87 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a stress-i

88 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherit

89 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherit

90 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherit

91 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by

92 efficacy of flecainide for catecholaminergic polymorphic ventricular tachycardia (CPVT) is unclear.

93 rgent clinical features of catecholaminergic polymorphic ventricular tachycardia (CPVT) or long QT sy

94 ong-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) represent tre

95 sms of arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia (CPVT) require spont

96 type 2 knockout) model of catecholaminergic polymorphic ventricular tachycardia (CPVT) was used for

97 gene (RYR2) cause dominant catecholaminergic polymorphic ventricular tachycardia (CPVT), a leading ca

98 utosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although iso

99 Catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited

100 In catecholaminergic polymorphic ventricular tachycardia (CPVT), cardiac Purk

101 These arrhythmias include catecholaminergic polymorphic ventricular tachycardia (CPVT), certain case

102 of concealed LQT1, namely catecholaminergic polymorphic ventricular tachycardia (CPVT), may also und

103 c Ca(2+) release events in catecholaminergic polymorphic ventricular tachycardia (CPVT), yet evidence

104 em cells (hiPSCs) model of catecholaminergic polymorphic ventricular tachycardia (CPVT).

105 at are associated with catecholamine-induced polymorphic ventricular tachycardia (CPVT).

106 e been associated with catecholamine-induced polymorphic ventricular tachycardia (CPVT).

107 T) may distinguish it from catecholaminergic polymorphic ventricular tachycardia (CPVT).

108 sion medicine, we focus on catecholaminergic polymorphic ventricular tachycardia (CPVT).

109 udden cardiac death called catecholaminergic polymorphic ventricular tachycardia (CPVT).

110 sudden death-predisposing catecholaminergic polymorphic ventricular tachycardia (CPVT).

111 ms of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT).

112 rial fibrillation (AF) and catecholaminergic polymorphic ventricular tachycardia (CPVT).

113 lethal familial arrhythmia catecholaminergic polymorphic ventricular tachycardia (CPVT).

114 lar tachycardia in humans [catecholaminergic polymorphic ventricular tachycardia (CPVT)].

115 assessed in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT; n=8) and in r

116 hythmias (in patients with catecholaminergic polymorphic ventricular tachycardia [CPVT]) reduced the

117 uced sudden cardiac death (catecholaminergic polymorphic ventricular tachycardia [CPVT]).

118 cise-induced sudden death (catecholaminergic polymorphic ventricular tachycardia [CPVT]).

119 tions in RYR2 cause type 1 catecholaminergic polymorphic ventricular tachycardia (CPVT1), a cardiac c

120 mutations can cause type-1 catecholaminergic polymorphic ventricular tachycardia (CPVT1), a lethal, a

121 olecular mechanism for the catecholaminergic polymorphic ventricular tachycardia (CPVT2) mutation, K2

122 Foremost are those with catecholaminergic polymorphic ventricular tachycardia due to abnormalities

123 tilide-treated patients, 15 (8.3%) developed polymorphic ventricular tachycardia during or soon after

124 In catecholaminergic polymorphic ventricular tachycardia, excess mortality wa

125 long QT syndrome (1/2) and catecholaminergic polymorphic ventricular tachycardia families (1/2) who w

126 QT prolongation (14%), torsades de pointe or polymorphic ventricular tachycardia/fibrillation (6% [su

127 Familial polymorphic ventricular tachycardia (FPVT) is characteri

128 and patients referred for catecholaminergic polymorphic ventricular tachycardia had the highest rate

129 ase dysfunction underlying catecholaminergic polymorphic ventricular tachycardia has only been invest

130 ome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia have been associated

131 Several types of polymorphic ventricular tachycardia have similar electro

132 1.65, p < 0.0001), ventricular fibrillation/polymorphic ventricular tachycardia (HR: 2.10, p < 0.000

133 to study long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardio

134 transmural repolarization in the genesis of polymorphic ventricular tachycardia in a canine model of

135 in leaky channels and cause exercise induced polymorphic ventricular tachycardia in humans [catechola

136 The initiation of polymorphic ventricular tachycardia in long QT syndrome

137 . high sympathetic tone, are associated with polymorphic ventricular tachycardia in LQTS patients.

138 nts manifest ventricular premature beats and polymorphic ventricular tachycardia in response to exerc

139 Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in RyR2(R4496C+/-) m

140 monstrate that azithromycin can cause rapid, polymorphic ventricular tachycardia in the absence of QT

141 The potential for producing polymorphic ventricular tachycardia in the rabbit model

142 Bidirectional and polymorphic ventricular tachycardias in CASQ2 KO mice in

143 rrhythmogenic rat model of catecholaminergic polymorphic ventricular tachycardia, induced by RyR2 gai

144 Catecholaminergic polymorphic ventricular tachycardia is a form of exercis

145 Catecholaminergic polymorphic ventricular tachycardia is a heritable arrhy

146 Catecholaminergic polymorphic ventricular tachycardia is an inherited dise

147 Catecholaminergic polymorphic ventricular tachycardia is an uncommon, pote

148 The recessive form of catecholaminergic polymorphic ventricular tachycardia is caused by mutatio

149 Catecholaminergic polymorphic ventricular tachycardia is characterized by

150 Catecholaminergic polymorphic ventricular tachycardia is directly linked t

151 Familial polymorphic ventricular tachycardia is due to a defect i

152 in-2 gene; this variant of catecholaminergic polymorphic ventricular tachycardia is less well charact

153 CASQ2 protein carrying the catecholaminergic polymorphic ventricular tachycardia-linked mutation D307

154 dling in mice carrying the catecholaminergic polymorphic ventricular tachycardia-linked mutation of r

155 We have shown that catecholaminergic polymorphic ventricular tachycardia-linked RyR2 mutation

156 terozygous mice carrying a catecholaminergic polymorphic ventricular tachycardia-linked RyR2 mutation

157 Patients with catecholaminergic polymorphic ventricular tachycardia manifest sinoatrial

158 ogenic mutation, as in the catecholaminergic polymorphic ventricular tachycardia mice studies, or mor

159 ythmias in CASQ2-defective catecholaminergic polymorphic ventricular tachycardia mice.

160 previously identified in a catecholaminergic polymorphic ventricular tachycardia model.

161 ic contractions (DCs) in a catecholaminergic polymorphic ventricular tachycardia mouse model with a m

162 dria structural defects in catecholaminergic polymorphic ventricular tachycardia myocytes and reduced

163 oxygen species emission in catecholaminergic polymorphic ventricular tachycardia myocytes.

164 ), supraventricular tachycardia (n = 1), and polymorphic ventricular tachycardia (n = 1).

165 thmogenic disease included catecholaminergic polymorphic ventricular tachycardia (n=13), Jervell and

166 ients with LQTS (N=40) and catecholaminergic polymorphic ventricular tachycardia (N=7) underwent vide

167 Sustained polymorphic ventricular tachycardia occurred in 2 of the

168 polarization that could potentially initiate polymorphic ventricular tachycardia or fibrillation.

169 iac arrhythmias, including catecholaminergic polymorphic ventricular tachycardia or long QT syndrome

170 forms of long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, or idiopathic ventr

171 entricular tachycardia, ventricular flutter, polymorphic ventricular tachycardia, or ventricular fibr

172 us to what was observed in catecholaminergic polymorphic ventricular tachycardia patients after exerc

173 rospective cohort study of catecholaminergic polymorphic ventricular tachycardia patients diagnosed b

174 to the SAN dysfunction in catecholaminergic polymorphic ventricular tachycardia patients.

175 model systems exhibited a catecholaminergic polymorphic ventricular tachycardia phenotype.

176 Polymorphic ventricular tachycardia (PMVT) has been repo

177 ation play a critical role in the genesis of polymorphic ventricular tachycardia (PVT) when QT interv

178 monomorphic ventricular tachycardia (MVT) or polymorphic ventricular tachycardia (PVT)/ventricular fi

179 sed by early afterdepolarizations (EADs) and polymorphic ventricular tachycardias (PVTs).

180 with long QT syndrome and catecholaminergic polymorphic ventricular tachycardia received routine bet

181 nd to be a protocol violation, had sustained polymorphic ventricular tachycardia requiring direct cur

182 NQ1, KCNH2, and SCN5A) and catecholaminergic polymorphic ventricular tachycardia-susceptibility gene

183 and long QT, Brugada, and catecholaminergic polymorphic ventricular tachycardia syndromes) should al

184 ase, such as hypertension, catecholaminergic polymorphic ventricular tachycardia, takotsubo cardiomyo

185 gment elevation in V1 through V3 and a rapid polymorphic ventricular tachycardia that can degenerate

186 diac death cases linked to catecholaminergic polymorphic ventricular tachycardia that feature lethal

187 tions in 2 genes linked to catecholaminergic polymorphic ventricular tachycardia, the first located i

188 rval prolongation, and the potentially fatal polymorphic ventricular tachycardia torsade de pointes,

189 tening cardiac arrhythmias, specifically the polymorphic ventricular tachycardia torsades de pointes.

190 ion of the cardiac action potential leads to polymorphic ventricular tachycardia (torsades de pointes

191 rdiogram and the morphologically distinctive polymorphic ventricular tachycardia ('torsades de pointe

192 Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) is a

193 Catecholaminergic polymorphic ventricular tachycardia type 2 (CPVT2) resul

194 ale and 1 of 2 female preparations developed polymorphic ventricular tachycardia/ventricular fibrilla

195 enting with malignant syncope and documented polymorphic ventricular tachycardia/ventricular fibrilla

196 tachycardia, n = 44; pause/asystole, n = 36; polymorphic ventricular tachycardia/ventricular fibrilla

197 function and an increased incidence of rapid polymorphic ventricular tachycardia (VT) and sudden card

198 rapy for the management of catecholaminergic polymorphic ventricular tachycardia (VT) in young patien

199 Catecholaminergic polymorphic ventricular tachycardia (VT) is a lethal fam

200 Polymorphic ventricular tachycardia (VT) is rare and gen

201 Polymorphic ventricular tachycardia (VT) without QT prol

202 yndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (VT), and short QT s

203 %) died suddenly, one with Holter-documented polymorphic ventricular tachycardia (VT).

204 uding long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia (VT).

205 st clinical probability of catecholaminergic polymorphic ventricular tachycardia was determined for a

206 specific genetic test for catecholaminergic polymorphic ventricular tachycardia was sent.

207 Polymorphic ventricular tachycardia was the most serious

208 All patients with sustained polymorphic ventricular tachycardia were successfully tr

209 icular cardiomyopathy, and catecholaminergic polymorphic ventricular tachycardia were the most common

210 Spontaneous and stimulation-induced polymorphic ventricular tachycardia with characteristics

211 genetic arrhythmia syndrome characterized by polymorphic ventricular tachycardia with physical or emo

212 n, and demonstrated facilitated induction of polymorphic ventricular tachycardia, without antecedent